Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
Clinical trial NCT07024862 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07024862
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-10-24
- Primary completion
- 2025-06-30
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.